Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
RSV, Pfizer
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to determine how much advantage will be gained from the nod as the Centers for Disease Control (CDC) will have to sign off on Abvrysvo's use in the wider age group.
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at increased risk. It is the first RSV vaccine indicated for adults younger than 50,
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age. Tuesday’s label expansion covers younger adults who are deemed at higher risk of RSV-related lower respiratory tract disease.
Pfizer gets a leg up in RSV as FDA clears jab for all adults
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the battle for market share.
Pfizer RSV vaccine Abrysvo gains expanded indication
The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus. Those conditions include obesity,
New FDA approval for Pfizer’s RSV vaccine Abrysvo
The US Food and Drug Administration (FDA) yesterday approved Abrysvo (respiratory syncytial virus vaccine). Developed and marketed by US pharma giant Pfizer, the vaccine is now authorized for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine,
Pfizer RSV Vaccine Abrysvo gets USFDA ok for high-risk adults aged 18-59
The approval for the vaccine, Abrysvo, in adults aged 18 to 59 was based on the results from a late stage trial in which two doses of the vaccine were teste
FDA Clears Pfizer RSV Vaccine for At-Risk Adults 18-59
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine
Reuters
14d
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
The shots are important for both
Pfizer
and GSK as they ... with the 2023 launch of
RSV
shot Abrysvo, but the company has expressed optimism about the
vaccine
in the U.S. this year.
15d
Low RSV and COVID vaccine usage is in line with investor expectations, but concerning: Jefferies
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
NK troops in RU confirmed
Linked to E. coli outbreak
Arlington visit records order
Trespassing charge upheld
Veteran film producer dies
2 US troops injured in raid
Kristy now Category 2
MO court upholds release
Dodgers legend dies
Lake Erie toxic algae study
To close 150 locations
First father-son duo in NBA
Funds corruption guilty plea
FDA approves RSV vaccine
Shooting trial delayed
US fines American Airlines
DOJ alleges racial bias
Giant ‘ghost’ fish spotted
GA election rules appeal
To appear on Rogan podcast
FAA finalizes safety rules
SK mulls arms for Ukraine
Brain stimulation study
Raises US growth forecast
Same-day pharmacy delivery
2025 Medicare changes
Six indicted for fraud in Ohio
US semiconductor tax credit
Hospitals' IV fluid shortage
Ordered to hand over assets
Reveals 2025 tax brackets
Feedback